Wennerberg Erik, Lhuillier Claire, Vanpouille-Box Claire, Pilones Karsten A, García-Martínez Elena, Rudqvist Nils-Petter, Formenti Silvia C, Demaria Sandra
Department of Radiation Oncology, Weill Cornell Medicine , New York, NY , USA.
Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA; Department of Hematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.
Front Immunol. 2017 Mar 13;8:229. doi: 10.3389/fimmu.2017.00229. eCollection 2017.
The immunostimulatory properties of radiation therapy (RT) have recently generated widespread interest due to preclinical and clinical evidence that tumor-localized RT can sometimes induce antitumor immune responses mediating regression of non-irradiated metastases (abscopal effect). The ability of RT to activate antitumor T cells explains the synergy of RT with immune checkpoint inhibitors, which has been well documented in mouse tumor models and is supported by observations of more frequent abscopal responses in patients refractory to immunotherapy who receive RT during immunotherapy. However, abscopal responses following RT remain relatively rare in the clinic, and antitumor immune responses are not effectively induced by RT against poorly immunogenic mouse tumors. This suggests that in order to improve the pro-immunogenic effects of RT, it is necessary to identify and overcome the barriers that pre-exist and/or are induced by RT in the tumor microenvironment. On the one hand, RT induces an immunogenic death of cancer cells associated with release of powerful danger signals that are essential to recruit and activate dendritic cells (DCs) and initiate antitumor immune responses. On the other hand, RT can promote the generation of immunosuppressive mediators that hinder DCs activation and impair the function of effector T cells. In this review, we discuss current evidence that several inhibitory pathways are induced and modulated in irradiated tumors. In particular, we will focus on factors that regulate and limit radiation-induced immunogenicity and emphasize current research on actionable targets that could increase the effectiveness of radiation-induced tumor vaccination.
放射治疗(RT)的免疫刺激特性最近引起了广泛关注,因为临床前和临床证据表明,肿瘤局部放疗有时可诱导抗肿瘤免疫反应,介导未受照射转移灶的消退(远隔效应)。RT激活抗肿瘤T细胞的能力解释了RT与免疫检查点抑制剂的协同作用,这在小鼠肿瘤模型中已有充分记录,并得到了免疫治疗难治性患者在免疫治疗期间接受RT时更频繁出现远隔反应的观察结果的支持。然而,RT后的远隔反应在临床上仍然相对罕见,并且RT对免疫原性较差的小鼠肿瘤不能有效诱导抗肿瘤免疫反应。这表明,为了提高RT的促免疫原性作用,有必要识别并克服肿瘤微环境中预先存在和/或由RT诱导的障碍。一方面,RT诱导癌细胞发生免疫原性死亡,并释放强大的危险信号,这些信号对于募集和激活树突状细胞(DC)以及启动抗肿瘤免疫反应至关重要。另一方面,RT可促进免疫抑制介质的产生,这些介质会阻碍DC的激活并损害效应T细胞的功能。在这篇综述中,我们讨论了目前的证据,即照射后的肿瘤中会诱导和调节几种抑制途径。特别是,我们将关注调控和限制辐射诱导免疫原性的因素,并强调目前对可增加辐射诱导肿瘤疫苗接种有效性的可操作靶点的研究。